181 related articles for article (PubMed ID: 37316954)
21. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.
Papp G; Changchien YC; Péterfia B; Pecsenka L; Krausz T; Stricker TP; Khoor A; Donner L; Sápi Z
Mod Pathol; 2013 Mar; 26(3):393-403. PubMed ID: 23174932
[TBL] [Abstract][Full Text] [Related]
22. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.
Papp G; Krausz T; Stricker TP; Szendrői M; Sápi Z
Genes Chromosomes Cancer; 2014 Feb; 53(2):168-76. PubMed ID: 24327545
[TBL] [Abstract][Full Text] [Related]
23. Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.
Schaefer IM; Al-Ibraheemi A; Qian X
Am J Clin Pathol; 2021 Jul; 156(2):229-245. PubMed ID: 33608696
[TBL] [Abstract][Full Text] [Related]
24. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
Modena P; Lualdi E; Facchinetti F; Galli L; Teixeira MR; Pilotti S; Sozzi G
Cancer Res; 2005 May; 65(10):4012-9. PubMed ID: 15899790
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
26. INI1-deficient tumors: diagnostic features and molecular genetics.
Hollmann TJ; Hornick JL
Am J Surg Pathol; 2011 Oct; 35(10):e47-63. PubMed ID: 21934399
[TBL] [Abstract][Full Text] [Related]
27. Prognostic determinants in epithelioid sarcoma.
Gasparini P; Facchinetti F; Boeri M; Lorenzetto E; Livio A; Gronchi A; Ferrari A; Massimino M; Spreafico F; Giangaspero F; Forni M; Maestro R; Alaggio R; Pilotti S; Collini P; Modena P; Sozzi G
Eur J Cancer; 2011 Jan; 47(2):287-95. PubMed ID: 20932739
[TBL] [Abstract][Full Text] [Related]
28. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity.
Agaimy A
Adv Anat Pathol; 2014 Nov; 21(6):394-410. PubMed ID: 25299309
[TBL] [Abstract][Full Text] [Related]
29. Hereditary SWI/SNF complex deficiency syndromes.
Agaimy A; Foulkes WD
Semin Diagn Pathol; 2018 May; 35(3):193-198. PubMed ID: 29397238
[TBL] [Abstract][Full Text] [Related]
30. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
[TBL] [Abstract][Full Text] [Related]
31. Epithelioid Sarcoma Arising in a Long-Term Survivor of an Atypical Teratoid/Rhabdoid Tumor in a Patient With Rhabdoid Tumor Predisposition Syndrome.
Baker TG; Lyons MJ; Leddy L; Parham DM; Welsh CT
Pediatr Dev Pathol; 2021; 24(2):164-168. PubMed ID: 33470921
[TBL] [Abstract][Full Text] [Related]
32. SWI/SNF deficient central nervous system neoplasms.
Cai C
Semin Diagn Pathol; 2021 May; 38(3):167-174. PubMed ID: 33762087
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic study of deciduoid mesothelioma using SMARCB1/INI1 immunohistochemistry and fluorescence in situ hybridization.
Kawai T; Ogata S; Nakashima H; Urabe S; Murakami I; Hiroshima K
Hum Pathol; 2019 Nov; 93():23-29. PubMed ID: 31445842
[TBL] [Abstract][Full Text] [Related]
34. SWI/SNF-deficient undifferentiated malignancies: where to draw the line
Tessier-Cloutier B; Kleinman CL; Foulkes WD
J Pathol; 2022 Feb; 256(2):139-142. PubMed ID: 34767264
[TBL] [Abstract][Full Text] [Related]
35. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
Le Quang M; Ranchère-Vince D; Le Loarer F
Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
[TBL] [Abstract][Full Text] [Related]
36. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix.
Kang EY; Tessier-Cloutier B; Duggan MA; Stewart CJR; Lee CH; Köbel M
Histopathology; 2021 Aug; 79(2):160-167. PubMed ID: 33432679
[TBL] [Abstract][Full Text] [Related]
37. Malignant rhabdoid tumors of the vulva versus epithelioid sarcomas: a clinicopathologic, immunohistochemical, and molecular genetics study.
Espinosa I; D'Angelo E; De Brot L; Prat J
Hum Pathol; 2023 May; 135():1-10. PubMed ID: 36863690
[TBL] [Abstract][Full Text] [Related]
38. Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid/rhabdoid tumor.
Kohashi K; Yamamoto H; Yamada Y; Kinoshita I; Oda Y
Hum Pathol; 2021 Jun; 112():1-8. PubMed ID: 33741347
[TBL] [Abstract][Full Text] [Related]
39. A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour.
Yasui H; Valind A; Karlsson J; Pietras C; Jansson C; Wille J; Romerius P; Backman T; Gisselsson D
J Pathol; 2020 Sep; 252(1):22-28. PubMed ID: 32542645
[TBL] [Abstract][Full Text] [Related]
40. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.
Kommoss FK; Tessier-Cloutier B; Witkowski L; Forgo E; Koelsche C; Köbel M; Foulkes WD; Lee CH; Kolin DL; von Deimling A; Howitt BE
J Pathol; 2022 Jun; 257(2):140-145. PubMed ID: 35218556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
